A new type of cancer treatment called antiangiogenic therapy is designed to block blood vessel growth in tumors. In a series of landmark clinical trials, five different antiangiogenic drugs — sunitinib (Sutent^®), sorafenib (Nexavar^®), bevacizumab (Avastin^®), temsirolimus (Torisel^®), and everolimus (Afinitor^®) — have shown significant benefit in the treatment of advanced kidney cancer. Each of these drugs is now approved by the U.S. Food and Drug Administration (FDA).